Mirum Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $29.6
- Today's High:
- $31.18
- Open Price:
- $30.33
- 52W Low:
- $17.315
- 52W High:
- $31.18
- Prev. Close:
- $30.43
- Volume:
- 555780
Company Statistics
- Market Cap.:
- $1.01 billion
- Book Value:
- 2.057
- Revenue TTM:
- $115.78 million
- Operating Margin TTM:
- -102.32%
- Gross Profit TTM:
- $64.69 million
- Profit Margin:
- -152.27%
- Return on Assets TTM:
- -19.99%
- Return on Equity TTM:
- -186.27%
Company Profile
Mirum Pharmaceuticals Inc had its IPO on 2019-07-18 under the ticker symbol MIRM.
The company operates in the Healthcare sector and Biotechnology industry. Mirum Pharmaceuticals Inc has a staff strength of 213 employees.
Stock update
Shares of Mirum Pharmaceuticals Inc opened at $30.33 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $29.6 - $31.18, and closed at $31.06.
This is a +2.07% increase from the previous day's closing price.
A total volume of 555,780 shares were traded at the close of the day’s session.
In the last one week, shares of Mirum Pharmaceuticals Inc have increased by +17.47%.
Mirum Pharmaceuticals Inc's Key Ratios
Mirum Pharmaceuticals Inc has a market cap of $1.01 billion, indicating a price to book ratio of 3.955 and a price to sales ratio of 12.5994.
In the last 12-months Mirum Pharmaceuticals Inc’s revenue was $115.78 million with a gross profit of $64.69 million and an EBITDA of $-113494000. The EBITDA ratio measures Mirum Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Mirum Pharmaceuticals Inc’s operating margin was -102.32% while its return on assets stood at -19.99% with a return of equity of -186.27%.
In Q2, Mirum Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 114.5%.
Mirum Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-4.77 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Mirum Pharmaceuticals Inc’s profitability.
Mirum Pharmaceuticals Inc stock is trading at a EV to sales ratio of 9.2994 and a EV to EBITDA ratio of -16.1848. Its price to sales ratio in the trailing 12-months stood at 12.5994.
Mirum Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $443.59 million
- Total Liabilities
- $58.20 million
- Operating Cash Flow
- $35.55 million
- Capital Expenditure
- $15.07 million
- Dividend Payout Ratio
- 0%
Mirum Pharmaceuticals Inc ended 2024 with $443.59 million in total assets and $0 in total liabilities. Its intangible assets were valued at $443.59 million while shareholder equity stood at $-496992000.00.
Mirum Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $58.20 million in other current liabilities, 4000.00 in common stock, $-496992000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $297.23 million and cash and short-term investments were $329.95 million. The company’s total short-term debt was $1,064,000 while long-term debt stood at $305.61 million.
Mirum Pharmaceuticals Inc’s total current assets stands at $383.52 million while long-term investments were $0 and short-term investments were $32.73 million. Its net receivables were $35.33 million compared to accounts payable of $14.45 million and inventory worth $8.51 million.
In 2024, Mirum Pharmaceuticals Inc's operating cash flow was $35.55 million while its capital expenditure stood at $15.07 million.
Comparatively, Mirum Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $31.06
- 52-Week High
- $31.18
- 52-Week Low
- $17.315
- Analyst Target Price
- $52
Mirum Pharmaceuticals Inc stock is currently trading at $31.06 per share. It touched a 52-week high of $31.18 and a 52-week low of $31.18. Analysts tracking the stock have a 12-month average target price of $52.
Its 50-day moving average was $26.36 and 200-day moving average was $24.31 The short ratio stood at 7.57 indicating a short percent outstanding of 0%.
Around 417.1% of the company’s stock are held by insiders while 8482.7% are held by institutions.
Frequently Asked Questions About Mirum Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company’s lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.